



## **Brian Villa, M.D.**

1901 SW 1<sup>st</sup> Street., 2<sup>nd</sup> Floor  
Miami, FL 33135

bvillamd@wellness-research-center.com

### **PROFESSIONAL EXPERIENCE**

#### **Clinical Research Investigator**

**2020 – Present**

Wellness Research Center

#### **Miami Dade Community**

**2021 – Present**

#### **Psychiatrist**

**2020 - Present**

Outpatient private practice - adolescent, adult, and geriatric populations

- Healthy Minds Medical Center - Doral, FL
- ABC's for Success - Coral Gables, FL

### **CLINICAL WORK HISTORY**

#### **Psychiatry Resident,**

**2016 - 2020**

**Larkin Hospital - Miami, Florida**

4-year ACGME accredited psychiatry training program included:

- In-patient and out-patient adult psychiatry, performing full biopsychosocial assessment with treatment and continuity of care.
- Received training in various psychiatry domains:
  1. Child and adolescent psychiatry
  2. Geriatric psychiatry
  3. Emergency psychiatry and on-call services Consultation liaison
  4. Addiction psychiatry Forensic psychiatry
  5. Community/crisis intervention
- Psychotherapy training in different modalities including:
  1. Psychodynamic psychotherapy
  2. Cognitive behavioral therapy
  3. Interpersonal therapy
  4. Motivational interviewing

Supervision was provided by psychiatrists or psychologists with psychotherapy training allowing for immediate formative feedback on psychotherapeutic techniques.

Brian Villa  
4/3/20  
1/20/2023



### **Research Fellow, 2014 - 2016**

- Assisted residents in formulating their ACGME required research and QI projects.
- Presented in American Heart Association Scientific Sessions, 2015  
Research topic: Cardioprotective effect of trait forgiveness on elevated heart rates in patients with schizophrenia.

### **EDUCATION**

Doctor of Medicine, Ross University School of Medicine, 2009 - 2014 Bachelor of Biology, Florida International University, 2003- 2008

### **LICENSES**

- Board Certified, American Board of Psychiatry and Neurology - 9/14/2021
- State of Florida - Medical Doctor (issued 12/7/2019)
- State of Florida - DEA (issued 12/16/2019)
- State of West Virginia - Medical Doctor, DEA (issued 7/22/2020)
- State of Virginia- Medical Doctor, DEA (issued 7/22/2020)
- Buprenorphine Waiver - Medication Assisted Treatment (issued 7/22/2020)

### **QUALITY IMPROVEMENT**

Project Lead - worked on implementing a mechanism to document Eforse (controlled medication registry) checks into EMR

### **CERTIFICATIONS**

- Brainsway Deep Transmagnetic Stimulation (TMS) certified
- ACLS/BLS certified - January 2021

### **CLINICAL RESEARCH EXPERIENCE**

2020 – Present Sub-Investigator/Dedicated Rater  
A Multi-Center, Double-Blind, Parallel Group, Randomized Controlled Study to Investigate Efficacy and Safety of Orally Administered “Study Drug” during a 12-week Treatment Period Compared to Placebo in Patients with Cognitive Impairment due to Alzheimer’s Disease

2020 – Present Sub-Investigator/Dedicated Rater  
Open Label Extension Study for Continued Safety and Efficacy Evaluation of in “Study Drug” Patients with Mild Alzheimer’s Disease



- 2020 – Present    Sub-Investigator/Dedicated Rater  
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of “Study Drug” in Subjects with Early Alzheimer’s Disease
- 2021 – 2022    Sub-Investigator/Dedicated Rater  
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with "Study Drug" in Patients with Major Depressive Disorder.
- 2021 – 2022    Sub-Investigator/Dedicated Rater  
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of “Study Drug” in the Treatment of Agitation in Patients with Dementia
- 2021 – 2022    Sub-Investigator/Dedicated Rater  
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of “Study Drug” in the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type
- 2021 - 2021    Sub-Investigator/Dedicated Rater  
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of "Study Drug" as Adjunctive Therapy in Adults with Major Depressive Disorder.
- 2018 - 2022    Sub-Investigator/Dedicated Rater  
A Phase II Randomized, Double-Blinded, Placebo-Controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of "Study Drug" Once Daily over 12-week Treatment Period in Patients with Schizophrenia.